Recruiting

New drug combined with chemotherapy for newly diagnosed advanced ovarian cancer

Plain-English translation of NCT06437353 on ClinicalTrials.gov ↗ · Source last updated November 2024 · Translation generated June 2026 · How we translate trials

Read our Ovarian Cancer research guide →

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether surufatinib, a new type of medication, works better when combined with standard chemotherapy drugs ( and carboplatin) to treat newly diagnosed advanced ovarian cancer. After the initial chemotherapy, patients will continue taking the medication as a maintenance therapy, with some patients also receiving a second medication called olaparib depending on their tumor's genetic characteristics.

Advanced ovarian cancer has a high risk of coming back even after surgery and standard chemotherapy. This trial is exploring whether adding this new medication to standard treatment can improve outcomes and help prevent the cancer from returning.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been newly diagnosed with advanced ovarian cancer (stage III or IV) with high-risk features, such as incomplete surgical removal, stage IV disease, or fluid around your organs
you have already had surgery to remove the cancer before starting this trial
you are in good enough health to tolerate treatment (ECOG performance status 0-2)
you can start treatment within 12 weeks after your surgery
your blood counts and organ function (liver, kidneys) are adequate based on recent blood tests

You likely don't qualify if…

you have previously taken anti-angiogenic drugs (medications that block blood vessel growth) such as bevacizumab or similar therapies
you are pregnant or breastfeeding
you have had significant bleeding in the past 3 months or blood clots or stroke in the past year
you have uncontrolled high blood pressure, heart disease, or serious heart rhythm problems
you have a history of HIV, immunodeficiency, or have received an organ transplant

What participation looks like

You will receive standard chemotherapy infusions ( and carboplatin) once every 3 weeks for 6 cycles. Starting with the second cycle, you will also take the new medication by mouth daily. After chemotherapy ends, you will continue the medication as a long-term maintenance therapy, and if your tumor has certain genetic features, you may also take a second medication (olaparib) for up to 2 years. You will have regular blood tests and imaging scans to monitor how the cancer is responding and watch for any side effects.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(1 site)

China

Anhui Cancer Hospital, Hefei, Anhui